Treatment of Multiple Myeloma: Best Practices from UPMC and Satellites

A panel of experts on multiple myeloma discuss newly diagnosed patients and factors that determine transplant eligibility.

Comprehensive insights on quadruplet therapy regimens and the risk stratification process for patients with multiple myeloma.

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

Expert perspectives on the practical applications of consolidation and maintenance therapies for patients with multiple myeloma.

The panel discusses the effect minimal residual disease (MRD) has on treatment selection and provides insights on the treatment of younger patients with standard risk.

Multiple myeloma specialists outline frailty assessment practices and discuss how frailty informs treatment decisions.

The expert panel provides clinical insights on the role of CAR T-cell therapy and factors that influence treatment selection in the second line and beyond.

A panel of multiple myeloma specialists discuss emerging data and ongoing research that are informing treating paradigms for patients with multiple myeloma.

An overview of bispecific antibodies available for the treatment of patients with relapsed/refractory multiple myeloma.

Clinical insights on selecting the right bispecific antibody for the right patient and an overview of barriers seen in community practice.

The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.